Experts Warn ‘Miracle’ Weight-Loss Drugs May Lead to Bone Fragility
Experts are raising alarms about the potential risks associated with ‘miracle’ weight-loss drugs like Ozempic and Wegovy, warning they may contribute to increased fractures and brittle bones.
These drugs can decrease body weight by up to 20%, but emerging studies suggest they could have detrimental long-term effects on bone density.
Recent research presented at the American Society for Bone and Mineral Research has illuminated these concerns.
One particular study published in the medical journal JAMA analyzed 200 individuals using the drugs, discovering they experienced reduced bone mineral density in the hip and spine compared to those receiving a placebo or solely engaging in exercise.
This reduction in bone mineral density indicates that patients using these weight-loss injections may face an elevated risk of developing osteoporosis, a condition characterized by fragile bones.
Experts have warned ‘miracle’ weight-loss drugs like Ozempic and Wegovy could lead to fractures and brittle bones
Additional studies have confirmed that users of these medications may experience decreased bone mineral density, particularly in critical areas like the hip and spine.
Dr. Taher Mahmud, founder of the London Osteoporosis Clinic, commented: “The weight-loss benefits are undeniable, but there’s also evidence indicating loss of lean mass and bone density, which is especially concerning for patients with pre-existing conditions like osteoporosis who are at risk of fractures.”
Dr. Mahmud added that the data is particularly worrying for individuals already susceptible to osteoporosis or fractures, such as those living with obesity or type 2 diabetes.
Ozempic and Wegovy belong to a class of drugs known as GLP-1 agonists, which work by reducing hunger sensations.
Last week, the government announced it would begin offering these drugs to unemployed individuals, raising concerns amongst experts who fear that an increase in their use could lead to a rise in osteoporosis rates.
Dr. Mahmud emphasized the importance of exercise for those taking GLP-1 medications: “Strength training, along with cardiovascular exercise, should be promoted to help protect against muscle and bone loss.”
He further stated, “Tackling obesity is essential for our nation, but it is crucial that we combine medical interventions with education and support to ensure individuals on GLP-1 agonists understand the importance of proper nutrition and weight-bearing exercise.”